Phenogen Sciences has announced the availability of BREVAGen Breast cancer risk assessment test for women at above average risk of developing estrogen-receptor positive breast cancer.

The risk assessment test, which combines clinical and genetic factors, examines a woman's clinical risk factors, such as lifetime exposure to estrogen, along with scientifically validated genetic markers to find out each patient's personalized five-year and lifetime risk of developing breast cancer.

The Breast Center of Austin MD Owen Winsett said breast health plans identify lifestyle changes that a patient can adopt to reduce the risk and provide them with motivation to follow a personalized surveillance / monitoring plan.

"By utilizing the BREVAGen breast cancer risk assessment test, 80% of women with little or no family history of breast cancer are able to identify their breast cancer risk and take appropriate action thus increasing their chances for survival," Winsett added.

The BREVAGen predictive risk test is administered using a non-invasive oral-swab and will be analyzed to deliver a comprehensive genetic risk prediction report to physicians that reviews the patient.

The relative risk score from seven genetic markers, called single nucleotide polymorphisms, will be combined with factors that comprise the patient's clinical and reproductive history to calculate the patient's risk of breast cancer.